Unresectable Hepatocellular Carcinoma Clinical Trials

19 recruiting

Unresectable Hepatocellular Carcinoma Trials at a Glance

25 actively recruiting trials for unresectable hepatocellular carcinoma are listed on ClinicalTrialsFinder across 6 cities in 21 countries. The largest study group is Phase 2 with 10 trials, with the heaviest enrollment activity in Guangzhou, Nanjing, and Baltimore. Lead sponsors running unresectable hepatocellular carcinoma studies include Mayo Clinic, Peking University Cancer Hospital & Institute, and Zhongda Hospital.

Browse unresectable hepatocellular carcinoma trials by phase

Treatments under study

About Unresectable Hepatocellular Carcinoma Clinical Trials

Looking for clinical trials for Unresectable Hepatocellular Carcinoma? There are currently 19 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Unresectable Hepatocellular Carcinoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Unresectable Hepatocellular Carcinoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 25 trials

Recruiting
Phase 1

A Study of SHR-2524 Plus Bevacizumab in the First-line Treatment of Advanced Hepatocellular Carcinoma

Advanced Unresectable Hepatocellular Carcinoma
Suzhou Suncadia Biopharmaceuticals Co., Ltd.36 enrolled2 locationsNCT07478302
Recruiting
Phase 2

Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma

Hepatocellular CarcinomaUnresectable Hepatocellular Carcinoma
University of Miami30 enrolled1 locationNCT06902246
Recruiting
Phase 2

Evaluation of RBS2418 in Combination With Tremelimumab Plus Durvalumab in Participants With Advanced Unresectable Hepatocellular Carcinoma

Advanced Unresectable Hepatocellular Carcinoma
Riboscience, LLC.220 enrolled4 locationsNCT07175441
Recruiting
Phase 1Phase 2

Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body.

Hepatocellular CarcinomaMetastatic Hepatocellular CarcinomaUnresectable Hepatocellular Carcinoma+4 more
Pfizer138 enrolled11 locationsNCT07227012
Recruiting
Phase 1Phase 2

Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer

Stage III Hepatocellular Carcinoma AJCC v8Stage IV Hepatocellular Carcinoma AJCC v8Unresectable Hepatocellular Carcinoma+3 more
Mayo Clinic85 enrolled1 locationNCT03942328
Recruiting

An Observational Study to Learn More About How Well a Treatment Works When Given After Treatment With Atezolizumab and Bevacizumab or Another Similar Combination of Drugs in Adults With Liver Cancer That Cannot be Treated With Surgery

Unresectable Hepatocellular Carcinoma
Bayer300 enrolled20 locationsNCT06117891
Recruiting
Phase 3

TACE Plus Camrelizumab and Apatinib for Unresectable Hepatocellular Carcinoma

Unresectable Hepatocellular CarcinomaApatinibCamrelizumab+1 more
Guohui Xu101 enrolled1 locationNCT06485466
Recruiting
Phase 1Phase 2

A Multicenter Clinical Study of Combined Therapy for Unresectable Hepatocellular Carcinoma

Unresectable Hepatocellular Carcinoma
West China Hospital33 enrolled1 locationNCT07482059
Recruiting
Phase 1Phase 2

Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Metastatic Triple-Negative Breast Carcinoma+97 more
Mayo Clinic132 enrolled1 locationNCT05269381
Recruiting
Phase 1

Atezolizumab+Bevacizumab+SBRT in Unresectable HCC

Unresectable Hepatocellular Carcinoma
Massachusetts General Hospital20 enrolled3 locationsNCT05096715
Recruiting
Not Applicable

Comparison of Response Between Combination of Transarterial Chemoembolization and Lenvatinib Therapy Versus Lenvatinib Monotherapy in Patients With Unresectable Hepatocellular Carcinoma

Unresectable Hepatocellular Carcinoma (HCC)
Bangladesh Medical University40 enrolled1 locationNCT07408804
Recruiting
Phase 1

MDN-001 Injection for the Treatment of Unresectable Primary Hepatocellular Carcinoma.

Unresectable Hepatocellular Carcinoma (HCC)Hepatoma
Suzhou Mednovo Yi Medical Technology Co., Ltd.40 enrolled8 locationsNCT07391839
Recruiting
Not Applicable

Downstaging Unresectable Hepatocellular Carcinoma to Resectable Disease With Combined Immunotherapy and Stereotactic Beamed Radiotherapy: a Pilot Study

Unresectable Hepatocellular CarcinomaHCC - Hepatocellular Carcinoma
The University of Hong Kong30 enrolled1 locationNCT07305428
Recruiting
Phase 1

Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations

Solid TumorsMetastatic Hepatocellular CarcinomaAdvanced Solid Tumors+11 more
Tyra Biosciences, Inc100 enrolled16 locationsNCT06915753
Recruiting
Phase 2

Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer

Locally Advanced Hepatocellular CarcinomaMetastatic Hepatocellular CarcinomaStage III Hepatocellular Carcinoma AJCC v8+6 more
Academic and Community Cancer Research United122 enrolled16 locationsNCT05168163
Recruiting

The Impact of Emotional Stress on Immunotherapy Outcomes in Liver Cancer Patients: A Multi-Cohort Study

Unresectable Hepatocellular CarcinomaPsychological DistressHCC - Hepatocellular Carcinoma+2 more
Guilin Medical University, China700 enrolled5 locationsNCT07141056
Recruiting

Impact of Splenectomy on the Efficacy of Targeted Therapy and Immunotherapy in Unresectable HCC Patients With Cirrhotic Portal Hypertension

Unresectable Hepatocellular Carcinoma
Zhiyong Huang60 enrolled1 locationNCT06280313
Recruiting
Phase 3

Chinese HCC Efficacy Evaluation, Response and Safety Study of TareSphere

Unresectable Hepatocellular Carcinoma
Chengdu New Radiomedicine Technology Co. LTD.108 enrolled11 locationsNCT06900543
Recruiting
Phase 1Phase 2

Safety and Efficacy of Tremelimumab+Durvalumab(MEDI4736)+TACE in Unresectable Hepatocellular Carcinoma

Unresectable Hepatocellular CarcinomaHepatocellular Carcinoma (HCC)
Yoon Jun Kim24 enrolled1 locationNCT06911255
Recruiting
Not Applicable

SIRT Versus cTACE for Unresectable HCC (CHANCE2506)

Unresectable Hepatocellular Carcinoma
Zhongda Hospital108 enrolled1 locationNCT06909708